Introduction
Genetic susceptibility plays an important role in the aetiology of inflammatory bowel disease (IBD). Several epidemiological studies have in particular shown high concordance rates of Crohn's disease (CD) in monozygotic twins [1, 2] . Molecular genetic association studies including candidate gene and genome-wide screening studies have suggested that several immune and inflammationrelated genes contribute to the pathogenesis of IBD [3, 4] .
In 2001, two groups reported the first susceptibility gene in CD, originally called NOD2, and more recently CARD15. The gene is located on chromosome 16q12, and its discovery was based on the linkage analysis of genome screening in IBD [5, 6] . CARD15 is expressed in monocytes, macrophages and intestinal epithelial cells [7] [8] [9] [10] . CARD15 is a member of the Ced4 superfamily that includes APAF-1 [11] and CARD4 [12, 13] . So far, more than 100 single nucleotide polymorphisms (SNPs) and mutations have been described in the CARD15 gene (http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?CMD = search&DB = snp). Only three mutations are independently associated with CD in Caucasian populations, 2104C-T in exon 4 (SNP8, R702W, Arg702Trp), 2722G-C in exon 8 (SNP12, G908R, Gly908Arg) and 3020insC in exon 11 (SNP13, L1007fs, Leu1007fsinsC) [14] . Several studies from different countries have been published on the prevalence of these three mutations in IBD. The results from European countries are summarized in Table 1 [5, . CD is most consistently associated with CARD15 L1007fs. One study also demonstrated a significantly increased prevalence of L1007fs in ulcerative colitis (UC) compared with controls [39] .
While simple heterozygous carriage of R702W, G908R or L1007fs is associated with about a three-fold increased relative risk for CD, compound heterozygous carriage or homozygous carriage results in a CD genotype relative risk (GRR) of 23-44 [5, 55, 56] . All three nucleotide changes are considered to be disease-associated mutations. Especially L1007fs has been demonstrated in vitro to be associated with a reduced activation of transcription factor nuclear k-B (NFkB) in mononuclear cells [6, 57, 58] . Recent data in a L1007fs knock-in mouse model, however, showed that carriage of L1007fs is associated with an elevated NFkB activity [59] . This mouse model is more in line with the clinical observation of elevated NFkB activity in patients with active CD [60] .
CARD15 is expressed in Paneth cells, which are specialized epithelial cells located in the mucosal crypts of Lieberkühn, and which are thought to play a protective role in the host against enteric flora [61] . While a high CARD15 expression has been demonstrated in CDaffected ileal Paneth cells, only weak expression was seen in normal ileal mucosa of CD and non-IBD individuals [10] . An antimicrobial defence mechanism of Paneth cells is secretion of antimicrobial peptides defensin-5 and defensin-6, which is diminished in CD-affected ileal Paneth cells. CARD15 L1007fs carriage showed a further defensin deficiency [27, 62] . Intestinal barrier function can also be harmed owing to an increased intestinal permeability, which is found in patients with CD and in their healthy relatives. Carriage of CARD15 L1007fs appeared to be associated with an increased intestinal permeability in these healthy first-degree relatives [63, 64] , except for one study [65] .
In multiple IBD-affected families, there is a high concordance rate for type of disease [66, 67] . Not much is known about the concordance rate of CARD15 mutation carriage in familial IBD. Recently, we have published our data about CARD15 L1007fs in familial CD. CD-affected relatives were more often concordant for L1007fs carriage than UC-affected relatives [68] . Otherwise, a Finnish study demonstrated in CD probands an association between CARD15 L1007fs carriage and familial IBD [20] .
The goal of this study was to determine the prevalence of the three CARD15 mutations R702W, G908R and L1007fs in Dutch patients with either familial or nonfamilial IBD. In familial IBD, CARD15 mutations were examined in IBD-affected and non-affected relatives. Moreover, a correlation with clinical phenotypes in IBD probands was sought.
Patients and methods

Patients, families and controls
Caucasian patients with IBD, meeting standard criteria [69] and attending the Erasmus MC University Medical Center Rotterdam (UMCR), were recruited for this study. Patients were classified as familial IBD if one or more relatives were known to have IBD. Probands, available affected relatives and non-affected relatives completed a questionnaire about IBD and other diseases. On the basis of the information supplied by their physician, the diagnosis was verified [69] . The disease phenotype of CD probands was classified according to the Vienna classification for CD [70] . UC probands were phenotyped according to the age at onset ( < 40 and Z 40 years), and the location of the disease (proctitis, left-sided colitis and extended colitis or pancolitis). Some patients and their relatives have been included in other studies [68, 71] . Caucasian controls were recruited at the Erasmus MC UMCR and have been described before [68, 71] . The study was approved by the Institutional Review Board of the Erasmus MC UMCR. All participants provided written informed consent.
DNA isolation
Genomic DNA was isolated from whole peripheral venous blood collected in ethylene diamine tetraacetic acidanticoagulated tubes (Becton Dickinson, Leiden, The Netherlands) using standard techniques. In some cases, DNA was isolated from Epstein-Barr virus-transformed lymphoblastoid cell lines, derived from peripheral venous blood collected in acid citrate dextrose solution containing tubes (Becton Dickinson) [72] .
Genotyping CARD15 R702W and G908R were determined by means of restriction enzyme analysis. First, the DNA regions of interest containing the mutation were amplified by polymerase chain reaction (PCR). For R702W (2104C-T in exon 4), the forward primer 5 0 -CAG CTG GGC AGC TTT GCT GC-3 0 and the reverse primer 5 0 -CAT GGC ATG CAC GCT CTT GG-3 0 were used. The R702W PCR product (448 bp) was purified by phenol extraction followed by ethanol precipitation, after which the PCR fragment was digested with 8 units of Hpa II (New England BioLabs, Beverly, Massachusetts, USA) for 4 h at 371C. Bands were visualized after separation on a 2% agarose gel containing ethidium bromide. The wild-type exon 4 resulted in fragments of 29, 54, 76 and 289 bp, while the R702W polymorphism resulted in fragments of 29, 130 and 289 bp. The G908R (2722G-C in exon 8) - CARD15 mutations in Dutch IBD van der Linde et al. 451
mutation was amplified using the forward primer 5 0 -CAC TTT GCT GGG ACC AGG AG-3 0 and the reverse primer 5 0 -ACT CCA TTG CCT AAC ATT GTG G-3 0 . The G908R PCR product (363 bp) was not further purified, and digested immediately with 4 units of HinP1 I (New England BioLabs) for 3 h at 371C followed by separation on a 2% agarose gel containing ethidium bromide. It resulted in one fragment of 363 bp in case of the wildtype allele, and in fragments of 168 and 195 bp in case of the G908R mutation.
CARD15 L1007fs (3020insC in exon 11) was determined by means of an allele-specific PCR reaction, followed by separation of the amplicons on an agarose gel as described previously [6, 68] .
When participants were found to be positive for CARD15 R702W, G908R or L1007fs, DNA sequencing of the corresponding PCR product was performed to confirm the mutation. Available relatives of these probands were screened for the same CARD15 mutation by DNA sequencing. Sequencing was performed on an ABI 310 genetic analyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands).
Statistics
Allele and genotype frequencies in CD, UC cases and in controls were determined. Associations were tested by comparing the allele frequencies of the CARD15 R702W, G908R and L1007fs mutations in cases with IBD and controls, using Fisher's exact test. The genotype frequencies in controls were tested for Hardy-Weinberg equilibrium (HWE) proportions. In case of association, the GRR and 95% confidence interval (CI) in heterozygous and homozygous carriers were estimated by comparing the genotype frequencies in cases and controls, and expressed as an odds ratio. When homozygous carriers were observed among the cases but not among the controls, the GRR in homozygous carriers versus non-carriers was computed using the expected number of homozygous carriers in controls based on HWE. A comparison of genotype frequencies between different groups was evaluated using Fisher's exact test [6] .
In familial IBD, the frequency of CARD15 mutations in affected family members was evaluated. We computed the expected number of carriers among affected relatives of probands carrying the mutation under Mendelian transmissions and assuming a small allele frequency. Taking 'p' as the allele frequency in the population, then the probability of carrying the mutation for first-degree relatives is 1 / 4 + 1 / 2 p, and for second-degree relatives this probability is 14 + 112 + p, etc. In this formula, the first term is the probability that relatives carry the same allele as the proband, and the second term is the probability that relatives carry another allele of the mutation. As an estimate of 'p', we used the observed frequency in the controls. We tested whether the observed number of carriers differed from the expected number of carriers. To this end, the variance of the observed number of carriers taking into account the correlation among affected relatives of one proband was computed. We used a normal distribution to derive a P value.
Associations between genotypes and IBD phenotypes were evaluated by w 2 statistics. For ordinal variables, we also applied the w 2 statistics for trend. In the case of small numbers, exact P values were computed.
Mean follow-up between groups was evaluated by the Student's t test.
All analyses were performed with SPSS software version 9.0 for windows (SPSS Inc., Chicago, Illinois, USA, 1998). Tables 3 and 4 . Seventy-eight (68%) CD and 34 (79%) UC patients had a positive family history for IBD. From these families, 45 CD-affected, 26 UCaffected, 100 non-IBD-affected blood-related and 19 non-IBD-affected non-blood-related family members were included. In addition, 77 unrelated healthy Caucasian adults were included as controls.
CARD15 mutations in inflammatory bowel disease patients and controls R702W
Twenty (17.5% of 114) patients with CD, four (9.3% of 43) with UC and nine (11.8% of 76) healthy controls (one control not tested) were carriers of the CARD15 R702W mutation. All mutation carriers were heterozygous. In controls, the genotype frequencies were in HWE (P = 0.59). The allele frequency of CARD15 R702W among patients with CD was 8.8%, 4.7% in UC patients and 5.9% in controls. The frequency of this missense mutation was not statistically different (P = 0.33) between patients with CD and controls, nor between patients with UC and controls (P = 0.77).
G908R
CARD15 G908R was found in 14 (12.3% of 114) patients with CD and in one (1.3% of 76) healthy individual (one control not tested). Only heterozygous carriers were found. In controls, the genotype frequencies were in HWE (P = 0.95). No UC-affected carriers were found. The allele frequency of the G908R mutation was 6.1% in CD-affected patients and 0.7% in controls, which was significantly different (P = 0.006). The GRR for CD in G908R carriers versus non-carriers was 10.5 (95% CI = 1.4-81.6, P = 0.005).
L1007fs
We found carriage of CARD15 L1007fs in 22 (19.3% of 114) patients with CD, two (4.7% of 43) in UC patients and three (3.9% of 77) in healthy controls. Three (2.6%) CD patients were homozygous carriers. In controls, the genotype frequencies were in HWE (P = 0.86). The allele frequency was 11.0% in CD patients, 2.3% in UC patients and 1.9% in healthy controls. CARD15 L1007fs was associated with CD (P = 0.001), but not with UC (P = 1.0). The GRR for CD of heterozygous compared with wild-type carriers was 5.1 (95% CI = 1.5-17.9, P = 0.005). On the basis of HWE, the estimate for the number of homozygous carriers in controls was 0.029, which yields a GRR for CD of homozygous versus wild-type carriers of 83.2 (95% CI = 0.31-N, P = 0.26).
Combined carriage of CARD15 mutations in inflammatory bowel disease patients and controls
The prevalence of CARD15 compound heterozygosity in CD probands was 2.6% (n = 3) for R702W/G908R, 3.5% (n = 4) for R702W/L1007fs and 0.9% (n = 1) for G908R/ L1007fs. In patients with UC and controls, no combined mutation carriage was found. The GRR for CD in patients with carriage of one mutation (R702W, G908R or L1007fs) versus wild-type carriers was 2.8 (95% CI = 1.3-5.7, P = 0.007). The GRR for CD of compound heterozygous or homozygous versus wild-type carriers was 17.8 (95% CI = 1.23-258.0, P = 0.001).
Prevalence of CARD15 mutations in familial and non-familial inflammatory bowel disease patients
Carriage of CARD15 R702W, G908R and L1007fs in CD-affected probands with a positive familial history of IBD was 15.4, 14.1 and 20.5%, respectively. In CD-affected probands with a negative familial history, the prevalences were 22.2, 8.3 and 16.7%, respectively. Although the G908R and L1007fs were more and the R720W was less prevalent in CD-affected probands with a positive familial history than in sporadic CD-affected probands, these differences were not statistically significant (P = 0.43, 0.54 and 0.80, respectively). Carriage of CARD15 R702W and L1007fs in UC-affected probands with a positive familial history of IBD was 11.8 and 2.9%, respectively. Prevalences in sporadic UC-affected probands were 0 and 11%, respectively. None of the prevalences between the two UC groups was significant different (P = 0.56 and 0.38, respectively).
As the group sizes of CD probands with a negative family history (n = 36), UC probands with a negative family history (n = 9) and UC probands with a positive family history (n = 34) are quite small, we also analysed the combined data. In familial IBD-affected probands (n = 112), carriage of CARD15 R702W, G908R and L1007fs was 14.3, 9.8 and 15.2%, respectively. In sporadic IBD-affected probands (n = 45), the prevalences were 17.8, 6.6 and 15.6%, respectively. These differences were not significant (P = 0.63, 0.54 and 1.0, respectively).
Prevalence of CARD15 mutations in inflammatory bowel disease-affected relatives
Available IBD-affected and unaffected relatives (up to the sixth degree) of probands positive for CARD15 R702W, G908R or L1007fs were screened for the mutation. Among first-degree IBD-affected relatives of CD probands carrying R702W, G908R and L1007fs mutations, the number of carriers with the same mutation was three out of six (50%), one out of four (12%) and five out of six (80%), respectively. Among affected relatives of CD probands carrying CARD15 L1007fs (n = 6), carriage of CARD15 L1007fs was significantly more frequent than expected (P < 0.001). Carriage of CARD15 R702W and G908R mutations in affected relatives was not different from what was expected. The pedigrees of the families with the L1007fs mutation are illustrated in Fig. 1 , and the statistical results are summarized in Table 2 . The number of available families of UC-affected probands was too low to perform statistical analysis.
Genotype-phenotype correlation
Carriage of CARD15 mutations and clinical phenotypes of all CD and UC probands were established. The results are summarized in Tables 3 and 4 . In CD, an association was found between carriage of at least one CARD15 mutation and disease behaviour (P = 0.023). Carriage of L1007fs was almost significant associated with disease behaviour (P = 0.052). In fact, in carriers of at least one CARD15 mutation and in carriers of L1007fs, a significant linear effect (trend) was found for inflammatory (B1), stricturing (B2) and penetrating (B3) disease (P = 0.006 and 0.017, respectively). For B1 disease eight (25.0% of 32), for B2 disease 10 (37.0% of 27) and for B3 disease 30 (54.5% of 55) patients were carriers of at least one mutation. Two (6.3%), five (18.5%) and 15 (27.3%) were carriers of L1007fs, respectively. It means that these carriers often show B2 disease, and even more often B3 disease. The mean follow-up of patients with B1 disease (12.4 years), however, was significantly shorter than patients with B3 disease (17.3 years, P = 0.016). Between B1 and B2 disease, and between B2 and B3 disease no significant differences were found for follow-up duration (P = 0.20 and 0.23, respectively). For UC, no association was found between CARD15 mutations and any phenotype (P Z 0.57).
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Discussion
The CARD15 gene has recently been described as the first susceptibility gene for CD [5, 6] . The CARD15 protein is mainly expressed in phagocytic cells. The CARD15 protein is able to induce NFkB after recognition of intracellular bacterial peptidoglycan [57, 73] . NFkB is an important regulator of genes involved in a proinflammatory response [74] .
Three mutations in the CARD15 gene have been reported to be independently associated with CD, including R702W, G908R and L1007fs [5, 53] . In this study, the allele and genotype frequencies of the three CARD15 mutations are comparable with those found in several other European studies (Table 1) . We found associations with CD only for G908R and L1007fs. Two other Dutch studies have been published about the prevalence of CARD15 mutations in IBD [43, 44] . We observed higher allele frequencies of G908R and L1007fs in CD than that found by Murillo et al. [43] and Linskens et al. [44] (6.0 versus 4.2-4.3 and 10.8 versus 7.9-8.4, respectively). These authors also found an association between the L1007fs mutation and CD, but not between In these six multiple inflammatory bowel disease (IBD)-affected families, in which the proband was positive for CARD15 L1007fs, carriage of CARD15 L1007fs in the IBD-affected relatives was significantly more frequent than expected (P < 0.001). -| -, Homozygous carriage of wild-type allele; + | -, heterozygous carriage of mutation; + | + , homozygous carriage of mutation , Crohn's disease; , ulcerative colitis.
454 No 6 CD and the G908R mutation. Neither of them evaluated the R702W mutation.
Carriage of two CARD15 mutations, either two alike (homozygosity) or two different (compound heterozygosity), has been reported in IBD as well. We found frequencies of homozygous and compound heterozygous carriership in CD comparable to those mentioned in the European literature (see references in Table 1 ). No combined carriage was found in UC and healthy controls, which is also in accordance with the literature.
As CARD15 mutations have only been found in a minority of patients with CD, it is likely that IBD is not a single disease but rather a group of genetically distinct diseases with similar clinical presentations [14] . Moreover, we recently reported homozygotic carriage of L1007fs mutations in unaffected first and second-degree relatives of a CD-affected sib-pair, suggesting that in these individuals the CARD15 mutation does not play a pathogenetic role [68] . In Fig. 2 , families are presented in which closely related CD-affected relatives differ in CARD15 mutation carriership status. It is therefore unlikely that the CARD15 mutations detected in the IBD probands contribute to the pathogenesis in the other IBD-affected family members. These individual families are clear examples of the complex multifactorial origin of IBD, in which no single genetic or environmental factor is necessary nor sufficient to cause disease [75] . Here, other (private) CARD15 mutations or mutations in other genes may be causative as recently reviewed. For example, nucleotide variations in the SLC22A4 and SLC22A5 genes (chromosome 5q31), and the DLG5 gene (chromosome 10q23) have also been found to be associated with CD [76] .
A positive family history is reported in about 5-30% of IBD cases, especially in CD [1] . Reports regarding an association between CARD15 mutations and a positive family history for IBD are, however, not consistent. While some studies reported a significant association [20, 40, 42, 55, 77] , most did not [15, 25, 33, 38, 41, 43, 53, [78] [79] [80] [81] [82] . In this study, we also found no association between CARD15 carriage and a positive familial history, although the number of patients without a familial history was relatively low compared with the group of familial patients.
Associations have been reported between CARD15 mutations and CD phenotypes, including stricturing disease [19] [20] [21] 23, 37, 41, 47, 53, 80, 83] , early onset disease [19, 26, 33, 34, 41, 53, 77, 80, 82, 84] , ileal and ileocolonic The association of carriage of L1007fs with disease behaviour did not reach significance (P = 0.052). Carriers of at least one mutation and carriers of L1007fs showed a significant trend for behaviour of disease (P = 0.006 and P = 0.017 respectively), including often stricturing and even more often penetrating disease.
a An association was found between carriage of at least one CARD15 mutation and disease behaviour (P = 0.023). [23, 34, 80] in some, but not in all studies [43, 44, 85] . In this study, an association was found only between the behaviour of disease in CD and carriage of at least one of the three CARD15 mutations. CD behaviour was almost significant associated with carriage of the L1007fs mutation. Carriers of at least one CARD15 mutations and carriers of L1007fs also showed a significant trend for stricturing and even more for penetrating disease behaviour. This may be a true phenomenon, but we cannot exclude the possibility that the observed differences were partly related to difference in follow-up between the groups, as changing patterns of disease have been observed [86] .
Not much is known about the carriage of CARD15 mutations in IBD-affected family members. By using an approach in which calculated allele frequencies were corrected for familial genetic dependency, we found that IBD-affected family members of CD probands with CARD15 L1007fs were carriers of this mutation significantly more often than expected. The statistical analysis for unaffected relatives is much harder to interpret as these relatives may still develop IBD in the future. Some authors have reported a higher frequency of CARD15 mutations in unaffected first-degree relatives of familial CD cases than in unrelated healthy controls [15, 38, 87] . These results can be criticized as multiple related healthy and CD-affected relatives were included, which may yield a deflated P value.
We found statistically significant higher concordance rates for carriage of CARD15 L1007fs in CD probands and their IBD-affected family members. On the other In these three families, it is demonstrated that common CARD15 mutations do not segregate with the disease, and it is therefore likely that in these families genes other than CARD15 contribute to the pathogenesis. -| -, Homozygous carriage of wild-type; + | -, heterozygous carriage of mutation; + | + , homozygous carriage of mutation. , Crohn's disease; , ulcerative colitis.
hand, the prevalence of L1007fs in probands with a positive family history was similar to probands with a negative family history. This may be due to small sample sizes or to the used definition of a positive family history. Larger families and families with more relatives of age near 30 years (median age of diagnosis of IBD in the Netherlands is 28-29 years [66] ) are more likely to be positive a priori.
In conclusion, we evaluated the CARD15 R702W, G908R and L1007fs mutations in Dutch IBD patients, and we confirmed the association of G908R and L1007fs with the susceptibility of CD. The prevalence of the three mutations did not differ between familial and sporadic IBD cases. Homozygosity and compound heterozygous carriage of the mutations was only found in CD (and not in UC). IBD-affected family members of L1007fs-positive CD probands were positive for L1007fs more often than expected. In CD, carriers of at least one CARD15 mutation and carriers of L1007fs were more likely to have stricturing and penetrating disease, which however might be the result of differences in follow-up duration.
